The price of a popular genetic test that predicts women's risk of breast cancer is likely to drop in the New Year after the agency that administers Medicare benefits said it would slash its reimbursement rate for the test by half.. The rate cut goes into effect on Jan. 1, 2014, with consequences for genetic-testing companies, particularly Myriad Genetics Inc., the dominant supplier of screenings for mutations in the genes known as BRCA1 and BRCA2. Medicare will pay a maximum of $1,440 for the BRCA test, a 48.5% decline from...
  